Media stories about Dimension Therapeutics (NASDAQ:DMTX) have been trending positive this week, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Dimension Therapeutics earned a media sentiment score of 0.28 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 44.3875747367862 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Shares of Dimension Therapeutics (DMTX) traded down $0.03 during midday trading on Thursday, hitting $5.95. 27,700 shares of the stock traded hands, compared to its average volume of 150,214. The firm has a market capitalization of $149.06 and a price-to-earnings ratio of -2.67. Dimension Therapeutics has a 1-year low of $1.05 and a 1-year high of $6.10. The company has a current ratio of 2.01, a quick ratio of 3.33 and a debt-to-equity ratio of 0.14.
Dimension Therapeutics (NASDAQ:DMTX) last issued its earnings results on Monday, November 6th. The biotechnology company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.20). Dimension Therapeutics had a negative return on equity of 240.95% and a negative net margin of 378.28%. The firm had revenue of $4.48 million for the quarter. equities analysts expect that Dimension Therapeutics will post -1.99 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Favorable Press Coverage Somewhat Unlikely to Affect Dimension Therapeutics (DMTX) Share Price” was first reported by Ticker Report and is the property of of Ticker Report. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3144602/favorable-press-coverage-somewhat-unlikely-to-affect-dimension-therapeutics-dmtx-share-price.html.
About Dimension Therapeutics
Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).
Receive News & Ratings for Dimension Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dimension Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.